title: Recent aspects of sunitinib therapy in patients with metastatic clear-cell renal cell carcinoma: a systematic review of the literature.
abstract: Sunitinib is an orally available inhibitor of multiple tyrosine-kinase receptors approved for the treatment of advanced clear-cell renal cell carcinoma (ccRCC), a disease which has habitually had a very poor patient survival rate. Although it has become the most widely used drug for this disease, it remains not completely clear the best treatment strategy with these agent. The aim of this review is to highlight the most recent and interesting aspects of the research on treatment of advanced ccRCC with sunitinib and eventually determine alternative treatment schedule to reduce the incidence of side effects; we also wanted to review recent biomarkers able to predict response to therapy and also to point out the mechanism of acquired resistance to this drug.
authors: Department of Clinic and Specialistic Sciences - Urology, Polytechnic University of the Marche Region - Azienda Ospedaliero - Universitaria Ospedali Riuniti, via Conca, 71, 60131, Ancona, Italy, d.minardi@univpm.it.
authors: Daniele
authors: D
authors: Minardi
authors: Luigi
authors: L
authors: Quaresima
authors: Matteo
authors: M
authors: Santoni
authors: Maristella
authors: M
authors: Bianconi
authors: Mario
authors: M
authors: Scartozzi
authors: Stefano
authors: S
authors: Cascinu
authors: Giovanni
authors: G
authors: Muzzonigro
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009362:Neoplasm Metastasis; D011758:Pyrroles / Q000627:therapeutic use*; D000077210:Sunitinib; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib
references: PLoS One. 2013;8(3):e59503
references: 23555683
references: J Urol. 2003 Aug;170(2 Pt 1):588-92
references: 12853836
references: Clin Cancer Res. 2005 May 15;11(10 ):3714-21
references: 15897568
references: Int J Cancer. 2008 Jul 15;123(2):395-400
references: 18464292
references: Science. 2011 Mar 25;331(6024):1559-64
references: 21436443
references: Cancer Res. 1994 Aug 1;54(15):4233-7
references: 7518352
references: Ann Oncol. 2013 Sep;24(9):2409-14
references: 23788753
references: BJU Int. 2014 Jul;114(1):81-9
references: 24215209
references: N Engl J Med. 2007 Jan 11;356(2):115-24
references: 17215529
references: Eur J Cancer. 2011 Sep;47(13):1955-61
references: 21600760
references: Int J Urol. 2013 May;20(5):478-83
references: 23113655
references: Cancer Res Treat. 2010 Sep;42(3):180-4
references: 20948925
references: Urol Oncol. 2014 May;32(4):480-7
references: 24321258
references: Pathol Int. 2006 Jul;56(7):359-67
references: 16792544
references: Anticancer Res. 2014 Jun;34(6):3177-84
references: 24922691
references: Onkologie. 2011;34(6):310-4
references: 21625184
references: Anticancer Res. 2013 Nov;33(11):5017-22
references: 24222145
references: Br J Cancer. 2009 Oct 20;101(8):1417-24
references: 19755989
references: Jpn J Cancer Res. 2002 Mar;93(3):340-5
references: 11927017
references: Asian Pac J Cancer Prev. 2013;14 (3):2101-5
references: 23679326
references: BJU Int. 2012 Dec;110(11 Pt C):E1131-7
references: 22712620
references: Jpn J Clin Oncol. 2006 Sep;36(9):564-9
references: 16861722
references: Br J Cancer. 2013 Jun 25;108(12 ):2470-7
references: 23695024
references: PLoS One. 2013 Sep 20;8(9):e74313
references: 24073208
references: Zhonghua Yi Xue Za Zhi. 2004 Oct 2;84(19):1620-4
references: 15569457
references: Virchows Arch. 2000 Apr;436(4):351-6
references: 10834538
references: Biochimie. 2005 Mar-Apr;87(3-4):361-8
references: 15781323
references: J Natl Cancer Inst. 2011 May 4;103(9):763-73
references: 21527770
references: Eur J Cancer. 2012 Jan;48(2):202-8
references: 22018713
references: Zhonghua Yi Xue Za Zhi. 2006 Jun 13;86(22):1526-9
references: 16854277
references: JAMA. 2006 Jun 7;295(21):2516-24
references: 16757724
references: Lancet Oncol. 2011 Nov;12 (12 ):1143-50
references: 22015057
references: Int J Urol. 2012 Oct;19(10 ):908-13
references: 22671963
references: Biochim Biophys Acta. 2014 Jan;1845(1):31-41
references: 24135488
references: Urol Oncol. 2015 Mar;33(3):113.e1-7
references: 25069421
references: Int J Cancer. 2015 Apr 1;136(7):1504-14
references: 25123505
references: Int J Immunopathol Pharmacol. 2008 Apr-Jun;21(2):447-55
references: 18547492
references: N Engl J Med. 2007 May 31;356(22):2271-81
references: 17538086
references: Angiogenesis. 2010 Mar;13(1):1-14
references: 20012482
references: Eur J Cancer. 2014 Apr;50(6):1084-9
references: 24559686
references: Science. 1993 May 28;260(5112):1317-20
references: 8493574
references: Br J Cancer. 2013 Jul 23;109 (2):332-41
references: 23807171
references: J Urol. 2005 Oct;174(4 Pt 1):1208-12
references: 16145371
references: J Clin Oncol. 2010 Oct 10;28(29):4513-20
references: 20837944
references: Genet Mol Res. 2014 Jul 04;13(3):5011-7
references: 25062489
references: Cancer Res. 2010 Feb 1;70(3):1063-71
references: 20103651
references: Cancer. 2009 May 15;115(10):2092-103
references: 19296514
references: Crit Rev Oncol Hematol. 2014 Dec;92 (3):208-17
references: 25151214
references: Eur J Cancer. 2009 Jan;45(2):228-47
references: 19097774
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: Hinyokika Kiyo. 2002 Apr;48(4):213-20
references: 12048933
references: J Clin Oncol. 2005 Jan 1;23 (1):133-41
references: 15625368
references: Int J Urol. 2009 Oct;16(10):801-7
references: 19811548
references: J Urol. 2014 Mar;191(3):611-8
references: 24018239
references: Lancet. 2008 Aug 9;372(9637):449-56
references: 18653228
references: Br J Cancer. 2013 Mar 19;108(5):1126-32
references: 23511629
references: Br J Cancer. 2007 Jun 18;96(12):1888-95
references: 17505508
references: Lancet Oncol. 2009 Aug;10 (8):757-63
references: 19615940
references: BJU Int. 2006 Oct;98 (4):756-62
references: 16827904
references: Blood. 1991 Mar 15;77(6):1218-27
references: 1705833
references: Anticancer Res. 2002 Nov-Dec;22(6C):4281-4
references: 12553070
references: Ann Oncol. 2010 Feb;21(2):431-2
references: 19945958
references: Curr Signal Transduct Ther. 2014 Dec;8(3):218-228
references: 25152704
references: J Exp Clin Cancer Res. 2009 Mar 20;28:40
references: 19302703
references: Pathol Oncol Res. 2007;13(2):145-8
references: 17607376
references: Eur Urol. 2010 Sep;58(3):398-406
references: 20633979
references: Anal Quant Cytol Histol. 2012 Feb;34(1):15-22
references: 22590815
references: Acta Oncol. 2014 Jan;53(1):103-12
references: 23421954
references: J Clin Oncol. 2009 Aug 1;27(22):3584-90
references: 19487381
references: Cancer Chemother Pharmacol. 2014 Jan;73(1):151-61
references: 24220935